Metagenomi Therapeutics, Inc. Earnings Per Share (Basic)
Metagenomi Therapeutics, Inc. (MGX) reported Earnings Per Share (Basic) of -$0.73 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.73.
- Metagenomi Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.61.
- Metagenomi Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.60.
- Metagenomi Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.55.
- Metagenomi Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$2.36.
- Metagenomi Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$2.36.
- Metagenomi Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$20.05.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.73 10-Q · filed 2026-08-10 | -$1.34 10-Q · filed 2026-08-10 | -$1.94 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$2.49 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2026-03-31 | -$0.61 10-Q · filed 2026-05-11 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$1.76 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$2.30 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$2.36 10-K · filed 2026-03-05 |
| 2025-09-30 | -$0.55 10-Q · filed 2025-11-12 | -$1.08 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.76 10-Q · filed 2025-11-12 | -$2.38 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-06-30 | -$0.54 10-Q · filed 2026-08-10 | -$1.21 10-Q · filed 2026-08-10 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$2.35 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-03-31 | -$0.68 10-Q · filed 2026-05-11 | -$1.30 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-05-11 |
| 2024-12-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.36 10-K · filed 2026-03-05 |
| 2024-09-30 | -$0.51 10-Q · filed 2025-11-12 | -$0.80 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.73 10-Q · filed 2025-11-12 | -$3.02 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.29 10-Q · filed 2025-08-12 | -$1.24 10-Q · filed 2025-08-12 | -$2.71 derived: net income ÷ weighted average shares · filed 2025-08-12 | -$4.65 derived: net income ÷ weighted average shares · filed 2025-08-12 |
| 2024-03-31 | -$1.19 10-Q · filed 2025-05-13 | -$3.62 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$6.90 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$9.86 derived: net income ÷ weighted average shares · filed 2025-05-13 |
| 2023-12-31 | -$5.67 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$11.49 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$15.31 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$20.05 10-K · filed 2025-03-17 |
| 2023-09-30 | -$5.82 10-Q · filed 2024-11-13 | -$9.64 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$14.38 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$3.82 10-Q · filed 2024-08-14 | -$8.56 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$4.74 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |